- KRYSTEXXA, combined with the immunomodulator methotrexate, has been able to improve the response rate in patients with refractory gout.
- Horizon to present results of study using both KRYSTEXXA and mycophenolate mofetil (immunomodulator) as another potential combination to treat refractory gout; Presentation expected November 7, 2020 at 5:20 p.m. ET.
- Company believes peak sales of KRYSTEXXA could reach >$ 1 billion.
- TEPEZZA exceeded expectations, and new guidance puts full-year 2020 sales of this drug >$650 million; Drug ultimately expected to make peak sales >$3 billion.
For further details see:
Horizon Provides A Good Long-Term Value Biotech With FDA-Approved Krystexxa And Tepezza